Last reviewed: June 9, 2026

Last updated: June 9, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

GLP-1 receptor agonists like semaglutide and tirzepatide slow stomach emptying to reduce hunger—a powerful weight loss mechanism that can inadvertently cause constipation in roughly 40% of users. The good news: constipation is manageable with the right approach, and you don't have to choose between your GLP-1 medication and digestive relief.

Why GLP-1 Medications Cause Constipation

GLP-1 receptor agonists work by activating receptors throughout your digestive system, including the stomach, small intestine, and colon. When these receptors are stimulated, they signal your gut to slow down food movement and increase feelings of fullness. This delayed gastric emptying is what makes GLP-1 therapy so effective for weight management—but it can also reduce the natural muscular contractions (peristalsis) that move stool through your colon, leading to constipation.

Clinical trials of tirzepatide, a dual GLP-1 and glucose-dependent insulinotropic peptide (GIP) receptor agonist, reported constipation in approximately 25–27% of participants at therapeutic doses. Semaglutide, a pure GLP-1 agonist, showed constipation rates of 15–20% in pivotal trials. The incidence typically rises as your dose increases over the first 2–3 months of treatment, then often stabilizes or improves as your body adapts.

Safe Laxative Options for Semaglutide and Tirzepatide Users

Osmotic laxatives like polyethylene glycol (MiraLAX) and magnesium citrate are generally considered first-line choices for GLP-1 users because they work locally in your colon without systemic absorption. These agents draw water into the bowel, softening stool and increasing bowel movement frequency. Unlike stimulant laxatives, osmotic options do not trigger strong muscular contractions that might interfere with GLP-1 signaling. Most gastroenterologists recommend starting with a standard dose—typically 17 grams of polyethylene glycol mixed into 4–8 ounces of water daily—and adjusting upward if needed.

Stool softeners containing docusate sodium (Colace) are another safe addition, especially when combined with osmotic laxatives. Docusate works by increasing fat content in stool, making it easier to pass without inducing bowel movement on its own. Bulk-forming agents like psyllium fiber (Metamucil) can also help, though they require adequate water intake—at least 6–8 glasses per day—to prevent them from worsening constipation.

Avoid stimulant laxatives such as bisacodyl (Dulcolax) and senna when possible, as they trigger intense muscular contractions that may increase abdominal discomfort in people already experiencing GLP-1-related gut changes. If osmotic and stool-softening options prove insufficient, discuss prescription options like linaclotide (Linzess) or plecanatide (Trulance) with your healthcare provider—these are gut-selective agents that may be safer in GLP-1 users than older stimulants.

Non-Medication Strategies to Prevent GLP-1-Related Constipation

Hydration is the single most important non-drug intervention. GLP-1 medications reduce appetite, which can lead to unintentional undereating and dehydration—both of which worsen constipation. Aim for at least 8–10 glasses of water daily, spread throughout the day. Warm fluids, particularly herbal tea and broth, are especially beneficial because they promote peristalsis and increase overall fluid intake without adding calories.

Dietary fiber should be increased gradually and intentionally. When starting GLP-1 therapy, your appetite naturally drops, which can reduce overall fiber consumption. To counteract this, focus on fiber-rich foods that align with your reduced appetite: cooked vegetables like broccoli and spinach, berries, ground flaxseed sprinkled on protein-based meals, and legumes in small portions. Increase fiber slowly over 1–2 weeks to allow your gut microbiome to adapt and prevent bloating.

Physical activity directly stimulates intestinal muscle contractions. Even light movement—a 15- to 20-minute walk after meals—can significantly reduce constipation risk. Abdominal massage in a clockwise direction for 2–3 minutes daily may also help stimulate bowel movement. These lifestyle modifications often prevent or resolve constipation entirely, making medication unnecessary for many GLP-1 users.

When to Contact Your Healthcare Provider About Constipation

Mild constipation lasting 2–3 days is expected during GLP-1 dose escalation and usually resolves with hydration and osmotic laxatives. However, severe or persistent constipation—especially if accompanied by severe abdominal pain, bloating, vomiting, or inability to pass stool for more than a week—requires immediate medical evaluation. These symptoms could indicate bowel obstruction, a rare but serious complication that requires urgent care.

PlexusDx patients taking tirzepatide injections or semaglutide should report constipation patterns to their provider during dose adjustments. Some individuals experience constipation only at higher doses, which your healthcare team can address by modifying your dosing schedule or exploring alternative GLP-1 formulations. The Precision Peptide Genetic Test available at PlexusDx analyzes variants in your GLP1R and MC4R genes—regions that influence both appetite regulation and gut motility—helping your provider predict which patients may be at higher risk for constipation and adjust strategies accordingly.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can I take a laxative every day while on semaglutide or tirzepatide?

Yes, daily osmotic laxatives like polyethylene glycol are safe for chronic use alongside GLP-1 therapy. However, aim to reduce reliance on laxatives as you progress through your dose titration—most users find that hydration, fiber, and activity manage constipation without daily medication after the first 1–2 months.

Will laxatives reduce the effectiveness of my GLP-1 medication?

No. Osmotic and stool-softening laxatives work locally in your colon and do not interact with GLP-1 or GIP receptors. They will not diminish semaglutide's or tirzepatide's weight loss or metabolic effects. Your dose will work as intended regardless of laxative use.

What's the difference between tirzepatide and semaglutide when it comes to constipation risk?

Tirzepatide activates both GLP-1 and GIP receptors, resulting in slightly higher constipation rates (25–27% in trials) compared to semaglutide (15–20%). This is partly because the dual mechanism has a broader effect on gut motility. PlexusDx offers both compounded tirzepatide injections starting at $249/month and semaglutide injections starting at $149/month, allowing your provider to choose based on your individual tolerance profile.

Are there any laxatives I should absolutely avoid on GLP-1 therapy?

Avoid strong stimulant laxatives like senna and bisacodyl as first-line options, as they can intensify abdominal cramping in GLP-1 users. Also avoid castor oil, which can interfere with nutrient absorption. Osmotic, stool-softening, and fiber-based options are always safer starting points—discuss any concerns with your healthcare provider before trying new products.

How can PlexusDx's genetic test help with constipation on GLP-1 therapy?

PlexusDx's Precision Peptide Genetic Test ($99 add-on after your first month) analyzes variants in GLP1R and MC4R genes, among 14 pathways and 49 peptides. Specific variants at rs6923761 (GLP1R) and rs17782313 (MC4R) predict how sensitive your gut is to GLP-1 signaling. This insight helps your provider anticipate constipation risk and tailor your treatment plan—whether that means adjusting your dose schedule, choosing semaglutide over tirzepatide, or starting preventive hydration and fiber strategies earlier.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves